Neos Therapeutics, Inc., a Grand Prairie, TX-based specialty pharmaceutical company with a late-stage pipeline of innovative extended-release products for Attention-Deficit Hyperactivity Disorder (ADHD), completed a $20.6m round of funding.
Backers included Presidio Partners, Crabtree Partners, CAC LLC, Delaware Street Capital, Burrill Life Sciences Capital Fund III and Essex Capital Corporation, as well as other investors.
The company intends to use the funds for the FDA review of NT-0102 as well as for the submission of NDAs for two additional ADHD drug candidates, an amphetamine XR-ODT and an amphetamine XR-Liquid Suspension.
Led by Vipin K. Garg, Ph.D., President and CEO, Neos Therapeutics initially focuses on ADHD with three proprietary products in late-stage development that provide patient-friendly dosage forms incorporating controlled and extended-release (XR) oral disintegrating tablets (ODT) and liquid suspensions. In addition, the company manufactures and markets a generic of Tussionex® (hydrocodone and chlorpheniramine) extended-release oral suspension for the treatment of cough and upper respiratory symptoms of a cold.